Current use of benzodiazepines in anxiety disorders

@article{Cloos2009CurrentUO,
  title={Current use of benzodiazepines in anxiety disorders},
  author={Jean-Marc Cloos and Val{\'e}rie Ferreira},
  journal={Current Opinion in Psychiatry},
  year={2009},
  volume={22},
  pages={90–95}
}
Purpose of review The aim of this study is to provide a review of articles published between July 2007 and August 2008 on the current use and rationale of benzodiazepines in anxiety disorders. Recent findings Recent review articles confirm selective serotonin reuptake inhibitors as first-choice drugs for treating anxiety disorders, alongside newer agents such as pregabalin or serotonin–norepinephrine reuptake inhibitors, and combined with cognitive–behavioural therapy. Benzodiazepines are still… 

Withdrawing Benzodiazepines in Patients With Anxiety Disorders

It is concluded that little evidence exists outside the usual principles of drug withdrawal but there are some promising leads.

Hydroxyzine for generalised anxiety disorder.

The data from the included studies provide some evidence that hydroxyzine is more effective than placebo for GAD, but due to the high risk of bias, the small number of studies and the overall small sample size, it is not possible to recommend hydroxyZine as a reliable first-line treatment in GAD.

The Efficacy and Safety of Clonazepam in Patients with Anxiety Disorder Taking Newer Antidepressants: A Multicenter Naturalistic Study

  • Sheng-Min WangJung-Bum Kim Kyoung-Uk Lee
  • Psychology, Medicine
    Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology
  • 2016
It is suggested that clonazepam is as efficacious as other benzodiazepines for the treatment of various anxiety disorders and the safety profile of clonazerepam was superior to the other Benzodiazepine groups in this study.

Benzodiazepines in long-term opioid therapy.

It has been argued that the availability of psychological therapies and selective serotonin reuptake inhibitors and serotonin-norepinephrine uptake inhibitors for anxiety disorders, and sleep hygiene and melatonin for insomnia have made the long-term administration of benzodiazepines largely avoidable.

A hospital based study: is the prescription of Benzodiazepine consistent with the guidelines?

The study showed that there was a huge variation regarding the duration of benzodiazepines use, ranging from the period of less than of 1 month to the maximum duration of 192 months or 16 years.

Benzodiazepines revisited--will we ever learn?

  • M. Lader
  • Medicine, Psychology
    Addiction
  • 2011
A series of adverse effects that continued to cause concern were noted, such as cognitive and psychomotor impairment, and dependence and abuse remain as serious problems despite warnings and guidelines.

Evidence-based pharmacotherapy of post-traumatic stress disorder (PTSD).

  • J. IpserDan J Stein
  • Psychology, Medicine
    The international journal of neuropsychopharmacology
  • 2012
The largest body of evidence for short- and long-term efficacy of medication currently exists for SSRIs, with promising initial findings for the selective noradrenergic reuptake inhibitor venlafaxine and the atypical antipsychotic risperidone.

Epidemiology of anxiolytic and hypnotic drug use in the general population in Norway

Women showed a higher proportion of use of psychotropic drugs than men, and there were also gender differences when studying mortality and incidence rates, which may lead us to question whether women suffer from more anxiety and depression than men.

Roles for pharmacists in improving the quality use of psychotropic medicines in residential aged care facilities

The key objective of this thesis was to assess if pharmacists could positively influence RACF psychotropic utilisation through the use of a series of facility-focused QUM strategies delivered in a dedicated intervention project.
...

References

SHOWING 1-10 OF 40 REFERENCES

Anxiety disorders: a comprehensive review of pharmacotherapies.

There is evidence from multiple randomized, placebo-controlled trials and meta-analyses of pharmacological treatments of anxiety disorders to support the use of selective serotonin reuptake inhibitors as first-line pharmacotherapy in these disorders, and a number of them have received US Food and Drug Administration approval for these indications.

Combination treatment with benzodiazepines and SSRIs for comorbid anxiety and depression: a review.

  • B. DunlopP. Davis
  • Psychology, Medicine
    Primary care companion to the Journal of clinical psychiatry
  • 2008
Benzodiazepines appear to improve treatment outcomes when an anxiety disorder co-occurs with depression or for depression characterized by anxious features, and may provide benefits both in terms of speed of response and overall response.

Effectiveness of benzodiazepines: do they work or not?

  • M. Lader
  • Psychology
    Expert review of neurotherapeutics
  • 2008
The conclusion is that efficacy was significantly higher for the drugs as compared with placebo; by contrast, no convincing evidence was found of any short-term effectiveness: and adverse effects were 1.5-times more frequent in the drug-treated patients.

Emerging anxiolytics

The understandings of mechanisms involved in the anxiety disorders are discussed, Mechanisms underlying the use of d-cycloserine, second generation antipsychotics and β-blockers are particularly exciting and emerging medications are reviewed.

Use of benzodiazepines and selective serotonin reuptake inhibitors in middle-aged and older adults with anxiety disorders: a longitudinal and prospective study.

Examination of patterns of medication use in middle-aged and older adults with diagnoses of panic disorder with or without agoraphobia, social phobia, or generalized anxiety disorder found that rates of BZ use were high among both the older and younger age groups and did not significantly decrease over time, after controlling for time in episode of their anxiety disorders.

Review: Benzodiazepines in generalized anxiety disorder: heterogeneity of outcomes based on a systematic review and meta-analysis of clinical trials

This systematic review of randomized controlled trials that compared any of the three best established benzodiazepines (diazepam, Lorazepam and aLprazolam) against placebo did not find convincing evidence of the short-term effectiveness of the Benzodiazepine in the treatment of GAD.

Glutamate and anxiety disorders

Novel pharmacologic agents that modulate particular receptors, ion channels, or transporters relevant to glutamatergic neurotransmission may represent a new approach to the treatment of anxiety disorders, with generally more favorable side effect profiles.

Does acute treatment with sedatives/hypnotics for anxiety in depressed patients affect suicide risk? A literature review.

  • N. YoussefC. Rich
  • Psychology, Medicine
    Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists
  • 2008
There is no clear evidence that their brief use early in depression increases suicide risk, and alternatives to sedative/hypnotics should be used if early adjunctive treatment for anxiety in depressed patients is thought to be indicated.

Benzodiazepines — a necessary evil? A survey of prescribing at a specialist UK psychiatric hospital

Benzodiazepines are quite frequently used in the management of a number of groups of difficult to treat patients and although largely not evidence based, some psychiatrists report a favourable risk—benefit ratio for benzodiazepine in the treatment of certain patients.